Clinical trials: Neoplasms, Solid Tumor
Advanced Cancer
Safety Study of FP-1039 To Treat Cancer
The primary purpose of this study is to evaluate the safety and tolerability of FP-1039, a new biologic treatment for cancer.
- Trial name
- NCT00687505
- Testing
- FP-1039
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Five Prime Therapeutics, Inc.
Solid Tumor Cancer
Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors
The study is a controlled, open-label exploratory clinical trial.
- Trial name
- NCT07146672
- Testing
- Super DC Vaccine
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)
This phase II MATCH treatment trial tests how well palbociclib (PD-0332991) works in treating patients with cancer that has certain genetic changes. Palbociclib (PD-0332991) is in a class of medications called kinase inhibitors.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT06390839
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced or Metastatic Solid Tumors
IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients
This is a multicenter, open-label, Phase Ib/II clinical trial to evaluate the safety, tolerability, and antitumor efficacy of IN10018 in combination with pegylated liposomal doxorubicin (PLD) or IN10018 in combination with PLD…
- Trial name
- NCT05830539
- Testing
- IN10018+PLD, IN10018+PLD+Toripalimab
- Where
- 7 sites in China
- Volunteers
- 68 people
- Sponsor
- InxMed (Shanghai) Co., Ltd.
Advanced Colorectal Cancer, Small Intestinal Cancer
JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
This study is to evaluate the safety, tolerability, pharmacokinetics and antitumor activity of JAB-21822 in combination with cetuximab in patients with advanced colorectal cancer，advanced small intestine cancer and advanced…
- Conditions
- Advanced Colorectal Cancer, Small Intestinal Cancer, Appendiceal Cancer
- Trial name
- NCT05194995
- Testing
- JAB-21822, Cetuximab
- Where
- 17 sites in China
- Volunteers
- 48 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Cancer
A Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors
The purpose of this study is to determine the maximum tolerated dose (MTD) and to explore the safety and anti-tumor activity of E7389 in combination with carboplatin in patients with advanced solid tumors.
- Trial name
- NCT00268905
- Testing
- E7389 + carboplatin AUC 5, E7389 + carboplatin AUC 6, E7389+carboplatin AUC 6
- Where
- 11 sites in United States, Austria and 1 more
- Volunteers
- 64 people
- Sponsor
- Eisai Inc.
Solid Tumors
Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer
The goal of this clinical research study is to find out if giving azacitidine with valproic acid plus carboplatin can help control advanced cancer. The safety of this treatment will be studied as well.
- Trial name
- NCT00529022
- Testing
- Azacitidine, Valproic Acid, Carboplatin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Solid Tumors (Any Localization)
Preclinical Safety Evaluation and First-in-Human Translational Study of [177Lu]Lu-TEFAPI-06
This study aims to systematically evaluate the safety, biodistribution, dosimetry, and preliminary therapeutic potential of [177Lu]Lu-TEFAPI-06 through an exploratory first-in-human (FIH) trial.
- Trial name
- NCT07299253
- Testing
- radionuclide therapy with [177Lu]Lu--TEFAPI-06
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Lanzhou University Second Hospital
Neoplasm Malignant
Pharmacokinetics and Safety Study of Cabazitaxel in Cancer Patients With Renal Impairment
Primary Objective: To assess potential impact of moderate and severe renal impairment on the pharmacokinetics of cabazitaxel Secondary Objective: To assess the safety of cabazitaxel in patients with various degrees of renal…
- Trial name
- NCT01527929
- Testing
- Cabazitaxel XRP6258
- Where
- 7 sites in Belgium, Italy and 3 more
- Volunteers
- 25 people
- Sponsor
- Sanofi
MTAP-deleted Solid Tumors
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have…
- Trial name
- NCT06188702
- Testing
- S095035, TNG462
- Where
- 20 sites in United States, Australia and 5 more
- Volunteers
- 61 people
- Sponsor
- Servier Bio-Innovation LLC
Unspecified Childhood Solid Tumor, Protocol Specific
Registration and Informed Consent Study for the Childhood Cancer Research Network
RATIONALE: Collecting informed consent from parents of children with cancer to register with the Childhood Cancer Research Network may help the study of cancer in the future.
- Trial name
- NCT00433394
- Testing
- cancer prevention intervention, educational intervention
- Where
- 21 sites in United States, Canada
- Volunteers
- 2,242 people
- Sponsor
- Children's Oncology Group
Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors
Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Phase I: Characterize safety and tolerability of ERW316 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimization/recommended dose for further clinical evaluation.
- Conditions
- Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Trial name
- NCT07570966
- Testing
- ERW316, Fulvestrant, Letrozole
- Sponsor
- Novartis Pharmaceuticals
Non-Hodgkin's Lymphoma, Solid Cancers
A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable
This is an open-label, Phase I, dose-escalation study using a 3 + 3 design to assess the safety, tolerability, and pharmacokinetics of orally administered GDC-0941 administered QD.
- Trial name
- NCT00876122
- Testing
- GDC-0941
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Genentech, Inc.
Solid Tumors
Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors
Co-selective inhibition of VEGFRs and FGFR has the potential benefit of blocking the two most relevant players in tumor angiogenesis and simultaneously targeting proliferation in FGF-driven tumors.
- Trial name
- NCT01283945
- Testing
- Lucitanib
- Where
- 4 sites in France, Italy and 1 more
- Volunteers
- 134 people
- Sponsor
- Institut de Recherches Internationales Servier
Advanced Solid Tumor
L-TIL in Patients With Malignancy Resistance to Anti-PD-1 Therapy
Safety and effectiveness of liquid tumor infiltrating lymphocytes in patients with advanced malignant tumors who have failed to anti-PD-1 therapy
- Trial name
- NCT04268108
- Testing
- liquid tumor infiltrating lymphocytes
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Henan Cancer Hospital
Gastric Cancer
Gastric Cancer Risk Factors Knowledge in European and Latinamerican Population
This study is divided into two parts: Part 1: An interventional study, with a pre-post study design to determinate the grade of knowledge of established GC risk factors.
- Trial name
- LEGACY-3 (NCT04019808)
- Where
- 8 sites in Argentina, Chile and 5 more
- Volunteers
- 800 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Advanced Solid Tumor
M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic profile of M9466 with and without tuvusertib or an ARPi and early signs of clinical activity of M9466 with tuvusertib in…
- Trial name
- NCT06421935
- Testing
- M9466, Tuvusertib, Abiraterone acetate
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 60 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Chemotherapy-induced Thrombocytopenia, Eltrombopag
Eltrombopag for Chemotherapy-induced Thrombocytopenia
To evaluate the efficacy and safety of eltrombopag to treat chemotherapy-induced thrombocytopenia in solid tumors
- Trial name
- NCT04600960
- Testing
- Eltrombopag
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Lymphoma, Solid Malignancy
PET Imaging of Subjects Using 124I-PU-AD
This is a first in-human, open-label pilot (microdose) study of the positron-emitting agent 124I-PU-AD in subjects with specific cancer types (solid malignancy, lymphoma, and/or myeloma) and/or Alzheimer's disease.
- Conditions
- Lymphoma, Solid Malignancy, Alzheimer Disease, Myeloma
- Trial name
- NCT03371420
- Testing
- PU-AD, PET Scan, Blood Draws
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Samus Therapeutics, Inc.
Advanced Malignant Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma
Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy
This phase Ib/II trial studies the best dose of temozolomide and how well it works with niraparib and atezolizumab in treating patients with solid tumors that have spread to other places in the body (advanced) and extensive-stage…
- Conditions
- Advanced Malignant Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
- Trial name
- NCT03830918
- Testing
- Atezolizumab, Niraparib, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Jonsson Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.